Glatiramer acetate (Copaxone®) therapy for multiple sclerosis

This publication has 65 references indexed in Scilit:

• Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®
  Journal of Neuroimmunology, 2001
• Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1
  Proceedings of the National Academy of Sciences, 2000
• Copolymer 1 acts against the immunodominant epitope 82–100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking
  Proceedings of the National Academy of Sciences, 1999
• Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis
  Proceedings of the National Academy of Sciences, 1997
• The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflections
  Immunology Letters, 1996
• The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease
  Zeitschrift für Neurologie, 1996
• New insights into the mechanism of action of copolymer 1 of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis
  Zeitschrift für Neurologie, 1996
• A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
  Neurology, 1991
• A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
  New England Journal of Medicine, 1987
• Multiple sclerosis: Trial of a synthetic polypeptide
  Annals of Neurology, 1982